Home > Pulmonology > ERS 2019 > Best of the Posters > COPD Patients Do Not Benefit from Azithromycin Therapy Longer than a Year

COPD Patients Do Not Benefit from Azithromycin Therapy Longer than a Year

Presented By
Dr Sander Talman, Amphia Hospital, the Netherlands
Conference
ERS 2019
Trial
Cohort study, COLUMBUS

A retrospective analysis of the COLUMBUS cohort found that prolonging azithromycin treatment over more than 1 year did not reduce COPD exacerbations.

The COLUMBUS trial included 92 adults with COPD who had ≥3 exacerbations within the year preceding the trial [1]. Treatment with 500 mg azithromycin or placebo 3 times a week over 12 months resulted in a significantly lower rate of exacerbation with a rate of 0.58 compared with placebo. The new question posed by Dr Sander Talman (Amphia Hospital, the Netherlands) and colleagues was whether continuing the bacteriostatic macrolide azithromycin for longer than 1 year would still entail an efficacious decrease in exacerbations [2].

The retrospective cohort study assigned the patients from the COLUMBUS investigation to a treatment or a control group, depending on their further therapy with azithromycin during the first year after the trial. Data was analysed for frequency of exacerbations, time to first inc...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on